Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symdeko and Trikafta for CF with W1282X Mutation
NCT03624101Phase 4Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of elexacaftor + tezacaftor + ivacaftor and tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by University of Alabama at Birmingham. Started Dec 2018; status: terminated.
02
Drugs
elexacaftor + tezacaftor + ivacaftortezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03624101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624101.